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Background: Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. Histone deacetylase
inhibitors are a new and promising drug family with strong anticancer activity. The aim of this study was to
examine the efficacy of in vitro and in vivo treatment with the novel pan-HDAC inhibitor belinostat on the growth
of human PDAC cells.
Methods: The proliferation of tumour cell lines (T3M4, AsPC-1 and Panc-1) was determined using an MTT assay.
Apoptosis was analysed using flow cytometry. Furthermore, p21Cip1/Waf1 and acetylated histone H4 (acH4)
expression were confirmed by immunoblot analysis. The in vivo effect of belinostat was studied in a chimeric
mouse model. Antitumoural activity was assessed by immunohistochemistry for Ki-67.
Results: Treatment with belinostat resulted in significant in vitro and in vivo growth inhibition of PDAC cells. This
was associated with a dose-dependent induction of tumour cell apoptosis. The apoptotic effect of gemcitabine was
further enhanced by belinostat. Moreover, treatment with belinostat increased expression of the cell cycle regulator
p21Cip1/Waf1 in Panc-1, and of acH4 in all cell lines tested. The reductions in xenograft tumour volumes were
associated with inhibition of cell proliferation.
Conclusion: Experimental treatment of human PDAC cells with belinostat is effective in vitro and in vivo and may
enhance the efficacy of gemcitabine. A consecutive study of belinostat in pancreatic cancer patients alone, and in
combination with gemcitabine, could further clarify these effects in the clinical setting.
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Pancreatic ductal adenocarcinoma (PDAC) is a highly
aggressive gastrointestinal tumour. It represents the
fourth leading cause of cancer related deaths in both
males and females in the western world [1]. Its resist-
ance to most forms of therapy such as chemo-, radio-,
immuno-, or targeted therapy contributes to the high
mortality of this malignancy [2]. Curative resection is
the only option to achieve long-term survival, but can be
performed in only 15–20% of newly diagnosed pancre-
atic cancer patients [3].* Correspondence: jens.werner@med.uni-heidelberg.de
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distribution, and reproduction in any mediumDespite numerous findings that have contributed to
the understanding [4] of PDAC pathogenesis, the reasons
for its aggressive biological behaviour remain unclear.
Therefore, new drugs for pancreatic adenocarcinoma are
urgently needed. One of the most encouraging fields in
modern oncological research is the investigation of epi-
genetics. Histone deacetylase inhibitors (HDACi) are typ-
ical representatives of this field of research, and may
serve as promising agents with strong anticancer activity.
The mechanism of HDACi activity is remodelling of
chromatin through a modification of histone molecules,
with consecutive initiation of cell differentiation, cell-
cycle arrest and induction of apoptosis. Additionally,
HDACi might affect neoplastic growth by regulating host
immune responses and tumour vasculature [5]. Clinical
studies have shown that HDACi can be administeredntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Dovzhanskiy et al. BMC Cancer 2012, 12:226 Page 2 of 9
http://www.biomedcentral.com/1471-2407/12/226safely in humans, and that treatment with these agents
seems to be beneficial for some types of cancers [6,7].
A new hydroxamate type HDACi, belinostat (previ-
ously called PXD101), has been shown to be a potent
anti-tumour agent with sub- to low micromolar IC50
potency in several tumour cell lines. In animal studies,
belinostat specifically inhibited tumour growth at non-
toxic concentrations [8,9]. Moreover, this compound has
recently been evaluated in clinical phase I and II studies
in both haematological and solid malignancies [10,11].
However, its efficacy in pancreatic cancer is unknown.
Therefore, the aim of this study was to examine the effi-
cacy of the novel pan-HDAC inhibitor belinostat on the
growth of human PDAC cells in vitro and in vivo.Methods
Cell culture and treatment
PDAC cell lines Panc-1 and AsPC-1 were obtained from
the American Type Culture Collection (Manassas, VA,
USA). T3M4 was a gift from R.S. Metzgar (Duke Univer-
sity, NC, USA). Cells were cultured in RPMI 1640
medium supplemented with 10% foetal bovine serum
(FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Invitrogen GmbH, Karlsruhe, Germany) at 37 °C in a
humidified 5% CO2 atmosphere. When cells were sub-
confluent, medium was changed on both untreated and
treated cells. Cells were treated with defined concentra-
tions of a belinostat (Topotarget, København, Denmark)
stock dissolved in DMSO. Control cells were grown fol-
lowing a similar protocol in medium supplemented with
equivalent volumes of PBS.MTT assay for cell proliferation
A 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium-
bromide (MTT) (Sigma-Aldrich Chemie, Steinheim,
Germany) assay was used to assess cell proliferation
reflected by metabolic activity of the cells. The cells were
seeded in 96-well plates at a density of 5000 cells/well in
250 μl of complete medium. After the cells became ad-
herent (in 24 h), they were exposed to belinostat (25nM,
50nM, 100nM, 300nM, 500nM, 800nM, or 1000nM) for
48 h. Cells exposed to PBS served as controls. After the
indicated times, 10 μl of MTT (5 mg/ml, dissolved in
PBS, pH 7.4) were added to each well and incubated for
4 h. After incubation, the culture medium was aspirated
and the plates were dried by inversion for about 15 min.
Subsequently, the formazan products were solubilised
with acidic isopropanol (100 μl for each well) and the
optical density was measured at λ= 570 nm with a Mul-
tiscan EX plate reader (Thermo Electron). All assays
were performed in triplicate. Proliferation in the control
group was set as 100%.Immunoblotting
After 24 h treatment with Belinostat (100 nM for T3M4
and ASPC or 300 nM for Panc-1), cells were washed
twice with ice cold PBS before lysis with SDS lysis buffer
(2% w/w SDS, 1 mM DTT, 10% v/v Glycerol, 62.5 mM
Tris–HCl pH6.8, 0.05%w/v Bromphenolblue). Protein
concentration was determined by BCA protein assay
(Pierce Chemical Co., Rockford, IL, USA). Cell lysates
(30 μg protein/lane) were separated on a 15% SDS/poly-
acrylamide gel and electroblotted on PVDF membrane
(Whatman, Maidstone, UK). Membranes were then
incubated in blocking solution (5% milk in 20 mM Tris–
HCl, 150 mM NaCl, 0.1% Tween-20), followed by over-
night incubation at 4 °C with anti acH4, CHIP-Grade
antibody (Upstate Biotechnology, Billerica, USA) at a di-
lution of 1:75,000, or rabbit polyclonal anti- p21Cip1/Waf1
(Abcam, Cambridge, UK) at a 1:200 dilution. The mem-
branes were then washed in TTBS and incubated with
secondary antibodies: POD conjugated donkey anti-
rabbit (Promega, Mannheim, Germany) at 1:150,000
dilution (blot for acH4) or POD conjugated goat anti-
rabbit IgG (GE Healthcare Limited, Buckinghamshire,
UK) at 1:2000 dilution (blot for p21Cip1/Waf1).
Antibody detection was performed using an enhanced
chemiluminescence reaction (Amersham Bioscience).
Equal lane loading was confirmed using anti-actin (Clone
AC-15) antibody (Sigma-Aldrich Chemie). The actin sig-
nal obtained after incubation with anti-actin antibody on
the same membrane was used as an internal control, in
addition to loading all lanes with the same amount
(30 μg) of protein. All assays were performed in triplicate.
For the semiquantitative analysis of the immunoblots,
densitometry using the ImageJ program was carried out,
and the signal intensity of acH4 or p21Cip1/Waf1 expres-
sion was normalised to its corresponding signal intensity
of actin.
Induction and analysis of cell death by flow cytometry
Belinostat was diluted in phosphate-buffered saline
(PBS) to a final concentration ranging from 100 to 1000
nM, according to the concentrations indicated in each
experiment. Gemcitabine (Synchem OHG, Felsberg,
Altenburg, Germany) was applied at a final concentra-
tion of 0.01 mM in PBS. All cells were treated and culti-
vated under the same conditions (37 °C with 5% CO2 in
RPMI 1640), and exposed to the drugs 24 h before the
experiments.
The viability of PDAC cells after exposure to belinostat
and/or gemcitabine was analysed using annexin V/propi-
dium iodide (PI)-staining (Annexin V-FITC Apoptosis
Detection Kit I, BD Biosciences, Heidelberg, Germany).
This method allows discrimination between early
(annexin V+/PI-) and late (annexin V+/PI+) apoptotic,
as well as necrotic (annexin V-/PI+) and viable (annexin
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the manufacturer’s instructions. Briefly, the cells were
suspended in a buffer solution (10 mM Hepes/NaOH at
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) at a final concen-
tration of 1 × 106 cells/ml. After addition of Annexin
V-FITC, the cells were incubated for 15 min at room
temperature without light exposure. Flow cytometry was
performed using the FACS LSR II system (BD Bios-
ciences). A total of 10,000 ungated events were acquired
for each sample, and data were analysed with the BD
FACS DivaW with the CSD module (BD Biosciences). In
order to determine late apoptotic cells, PI was added to
the samples. Flow cytometry was performed immediately
thereafter.
In vivo tumourigenicity study
A total of 300,000 T3M4 cells in 200 μl RPMI 1640
medium were injected subcutaneously behind the anter-
ior forelimb of four-week-old athymic mice through a
26-gauge needle. The injection sites were examined daily
for the appearance of tumours. Treatment was started
on the seventh day after tumour inoculation. Mice were
divided into groups receiving belinostat (0.1 mg/g,
5 ×weekly), gemcitabine (0.15 mg/g, 2 ×weekly), or a
combination of both (Belinostat at 0.1 mg/g, 5 ×weekly,
plus gemcitabine at 0.15 mg/g, 2 ×weekly) i.p., whereas
the control group (sham) received only PBS (20 μl/g,Figure 1 Proliferation of PDAC cells (MTT assay). Treatment with belino
in a dose-dependent manner. T3M4, AsPC-1 and Panc-1 cells were cultivate
was determined. Data are presented as mean± SEM. * p< 0.05 vs. control.5 ×weekly). Treatment was continued for 28 consecutive
days, and tumours were measured twice weekly with
Vernier callipers. Tumour volumes were calculated
using the formula: tumour volume = (L ×W²)/2, with L
representing the length and W the width of the tumour
[12].
The same treatment was performed after tumour in-
oculation by direct injection in the pancreatic tail via
laparotomy. In this case, the tumours were compared at
the end of 28- days of treatment.
After completion of treatment, the animals were sacri-
ficed, and tumours were excised, fixed, and embedded in
paraffin. The numbers of mice in each treatment cohort
was 6. All experiments on animals were approved in ac-
cordance with German law on the care and use of la-
boratory animals.
Immunohistochemistry
Paraffin-embedded tissue sections (2–3 mm thick) were
deparaffinised in xylene and rehydrated in progressively
decreasing concentrations of ethanol. Thereafter, slides
were placed in washing buffer. Antigen retrieval was car-
ried out by microwaving the tissue sections in 10 mM
citrate buffer for 10 min. Sections were then incubated
first with normal goat serum (DAKO Corporation, Car-
pinteria, CA, USA) for 45 min to block non-specific-
binding sites, and then with a mouse monoclonal Ki-67stat reduces the proliferation of pancreatic carcinoma cell lines in vitro
d with increasing concentrations of belinostat. After 48 h, cell viability
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was performed for 18 h at 4 °C. Slides were then rinsed
in washing buffer and incubated with a biotinylated sec-
ondary goat anti-mouse antibody (DAKO Corporation)
for 45 min at room temperature. The slides were then
washed in washing buffer, and each section was exposed
to 100 μl DAB-chromogen substrate mixture (DAKO
Corporation), then counterstained with Mayer’s haema-
toxylin. The sections were washed again, dehydrated in
increasing concentrations of ethanol, and mounted with
xylene-based mounting medium. Every staining was con-
trolled with a negative control. For semi-quantitative
analysis, slides were scored in a blinded manner by two
observers. Using 400-fold image magnification, the posi-
tive and negative stained cells were counted at three in-
dependent units area. Next, the percentage of the
positive stained cells was calculated.Figure 2 Apoptosis and necrosis in PDAC cell lines after treatment wi
tumour cells after treatment with belinostat, gemcitabine or belinostat + ge
fractions in the different PDAC cell lines. Belinostat increased apoptosis in a
Moreover, the combination of belinostat and gemcitabine significantly enh
mean± SEM. * p< 0.05 vs. control.Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). Analysis of variance (ANOVA) was used to
show an overall difference between groups, the Student
t test for pairwise comparison of normal distributed
parameters, and the Mann–Whitney U test for para-
meters without normal distribution. Significance was
defined as p< 0.05. Graphical presentations were per-
formed using GraphPad Prism version 4.02 for Windows
(GraphPad Software).
Results
Effects of belinostat in vitro
Antiproliferative effect of belinostat on pancreatic cancer
cells
Belinostat caused a significant dose-dependent decrease in
cell proliferation in all cell lines tested. The ED50th belinostat and (or) gemcitabine. The percentage of dying
mcitabine, stratified into early apoptotic, late apoptotic and necrotic
dose-dependent fashion in T3M4, AsPC-1 and Panc-1 cell lines.
anced apoptosis in T3M4 and Panc-1. Data are presented as
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~200nM for AsPC-1 and ~600 nM for Panc-1 (Figure 1).
Apoptosis induction in pancreatic cancer cells by belinostat
treatment
As shown in Figure 2, treatment with belinostat induced
dose dependent apoptosis in all cell lines tested. The dif-
ferences compared to control were significant at concen-
trations of 500 nM or more in all cell lines tested.
Belinostat increases gemcitabine-mediated apoptosis in
pancreatic tumour cells
When concomitant use of both drugs (500 nM belino-
stat and 0,01 mM gemcitabine) was tested in T3M4,
AsPC-1 and Panc-1 cells, the combined treatment sig-
nificantly enhanced the proapoptotic activity comparedFigure 3 Expression of acetylated histone H4 and p21Cip1/Waf1 after b
acetylation (A) and p21Cip1/Waf1 expression (B) after belinostat treatment (1
protein samples in each lane was confirmed using an anti-actin antibody. D
expression (B) after the treatment of the tumour cells with belinostat (perc
control.to gemcitabine treatment alone in Panc-1 (~3 fold) and
T3M4 (~1.5 fold) cells (Figure 2).
Inhibition of histone deacetylation after belinostat
treatment
In Western Blot analysis with an anti-ac-histone H4
antibody, treatment with belinostat significantly
increased acetylation of histone 4 in all cell lines tested
(Figure 3A).
Belinostat induces expression of p21Cip1/Waf1
In addition, belinostat was effective in increasing the
level of p21Cip1/Waf1, which is related to HDACi-induced
growth arrest in pancreatic carcinoma cells. Figure 3B
demonstrates the increased expression of p21Cip1/Waf1
after belinostat treatment in Panc-1 cells.elinostat treatment. Representative Western blot analyses of H4
00nM for T3M4 and AsPC-1, 300nM for Panc-1). Equal loading of
ensitometry shows increase of H4 acetylation (A) or p21Cip1/Waf1
entage of control). Data are presented as mean± SEM. * p< 0.05 vs.
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Tumours in the belinostat treatment group showed sig-
nificantly reduced growth in both subcutaneous and
intrapancreatic tumours compared with the control
group, in in vivo experiments (Figures 4A and B). The
combination of belinostat and gemcitabine therapy
showed no additional growth inhibition.
Routine hematoxylin/eosin histological examination
showed no morphological differences between the
tumours in the treatment and control groups. However,A
B
Figure 4 Growth inhibition of xenograft tumours. Subcutaneous (A) an
mice treated with PBS (sham), belinostat, gemcitabine or belinostat + gemc
measurable tumours at each time point. In summary, tumours in the treatm
the treatment groups were not significant. Data are presented as mean± Sanalysis of their proliferation rates (Figure 5) using an
anti-Ki-67 antibody, showed a significantly lower num-
ber of proliferating cells per unit area in the belinostat
group (47.8 ± 5.7 cells per high-power field) compared
with the control group (79.1 ± 2.2).
Discussion
PDAC remains a therapeutic challenge with a poor overall
prognosis. Only surgery with adjuvant chemotherapy can
achieve a long-term perspective in patients with localizedd intrapancreatic (B) xenograft tumour growth of T3M4 cells in nude
itabine. The mean of the tumour volume was calculated from
ent groups were smaller compared to sham. The differences between





Figure 5 Immunohistochemical analysis of cell proliferation in xenograft tumours. Proliferating cells in sham (A) and belinostat (B) groups
as assessed by an anti-Ki-67 antibody. The pictures were taken at 400-fold magnification. (C) Treatment with Belinostat led to a significant
decrease in proliferating cells. Data (% proliferating cells per unit area) are presented as mean± SEM. * p< 0.05.
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based on 5-FU or gemcitabine has been shown to im-
prove the survival of these patients [16]. However, even
under optimal treatment conditions, the 5-year survival
rate doesn’t exceed 25% [13]. Additionally, palliative
treatment in advanced tumour stages is associated with
a poor prognosis and a median survival of about
6 months. To improve this situation, investigation of
new therapeutic agents for PDAC treatment is essential.
The family of HDACi represents a novel approach in
oncological research. In defined - predominantly haem-
atological - tumour entities, HDACi have already passed
the stage of experimental research and been investigated
clinically [17]. Regarding PDAC, promising results have
been shown using SAHA, TSA, butyrate and some other
histone deacetylase inhibitors in experimental studies
[6,18-20]. Belinostat is a novel member of the family
with a distinct pan-HDAC inhibitory effect. It has been
shown to be strongly effective in experimental settings
of ovarian, bladder and colon cancer, as well as haemato-
logical tumour entities [9,21-24]. Consecutive clinical
trials have proven an anti-tumour effect of belinostat as
a monotherapy in T-cell lymphomas and thymomas. In
addition, belinostat has demonstrated beneficial effectsin combination with other anti-cancer drugs for the
treatment of ovarian and bladder cancer, CUP, multiple
myeloma and acute myeloid leukaemia. Despite these
findings, no data are available concerning belinostat in
the context of PDAC treatment. Consequently, in the
present study, the efficacy of belinostat for PDAC treat-
ment was investigated in experimental in vitro and
in vivo settings for the first time.
Comparable to the results of previous studies in blad-
der [8], colorectal [25] or hepatocellular carcinoma [21],
we found a strong dose dependent antiproliferative ac-
tivity of belinostat in three pancreatic cancer cell lines
(T3M4, Panc-1 and AsPC-1) with an IC50 concentra-
tion in the nanomolar range, similar to other tumour
entities [8,25].
This antiproliferative effect can be explained by a
strong proapoptotic activity in pancreatic cancer cells,
demonstrated by annexinV/propidium iodide staining.
This is in line with other studies on AML- [26] and
hepatocellular carcinoma cells [21], underlining that
apoptosis induction is an important mechanism of the
anti-tumourous effect of HDACi, and particularly beli-
nostat. As apoptosis induction is an important mechan-
ism of anti-cancer chemotherapy [27], we tested the
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bine. As described in studies with other HDACi like tri-
chostatin A [6] and 4-phenylbutyrate [18], the
combination of gemcitabine and belinostat strongly
enhanced the proapoptotic effects of each substance
alone. This may be due to the expression of proapoptotic
proteins like Caspase-8 and Bid, and activation of the
gemcitabine-mediated JNK-pathway [18].
Increase in histone H4 acetylation has been shown to
be helpful in monitoring belinostat activity [28]. Conse-
quently, we examined belinostat-dependent expression
of acH4 in PDAC cells. Acetylation of H4 was increased
in all cell lines tested, confirming the inhibitory effect of
belinostat on HDAC activity in pancreatic cancer cells.
Cyclin-dependent kinase inhibitor p21Cip1/Waf1 is a key
protein participating in cell cycle regulation. Previous
studies have shown that HDACi activates expression of
p21Cip1/Waf1 through enhanced histone acetylation around
the p21Cip1/Waf1 promoter [29]. We performed western
blot analysis with treated and control Panc-1 cells to clar-
ify the effect of belinostat on p21Cip1/Waf1 expression. Beli-
nostat induced an upregulation of p21Cip1/Waf1, as has
been described for other HDAC inhibitors in pancreatic
cancer [18,30]. Increased expression of p21Cip1/Waf1 in
these studies was associated with normalization of the cell
cycle and induction of apoptosis.
Regarding the effect of belinostat in vivo, we observed
that belinostat was an effective growth inhibitor of
T3M4 pancreatic cancer cells in a nude mouse model.
Mice treated with belinostat showed xenograft growth
inhibition for more than 28 days after tumour inocula-
tion, without any signs of toxicity. The reduction in the
tumour volume was associated with decreased cell pro-
liferation, as shown by Ki-67 immunohistochemistry.
Similar observations in in vivo tumour models were
shown in previous studies, e.g. in human ovarian cancer
s.c. xenografts; the efficacy of the treatment with belino-
stat was further enhanced when a combination therapy
with carboplatin was added [24]. Plumb et al. [22]
described a significant dose-dependent growth delay of
human colon tumour xenografts in mice after belinostat
treatment, without signs of toxicity.
In contrast to our in vitro observations, we could not
find an additional effect of combined therapy with beli-
nostat and gemcitabine in vivo. A possible explanation
for this discrepancy is the relatively high dosage of gem-
citabine administered in the in vivo study. This might
have covered a possible additional belinostat effect.
Conclusion
In summary, this preclinical study using in vitro and
in vivo pancreatic cancer models shows that belinostat is
effective as a monotherapy of pancreatic cancer, primarily
by inhibition of proliferation and induction of apoptosis.In vitro results revealed that belinostat can be successfully
combined with gemcitabine to potentiate induction of
apoptosis in the tumour cells. These findings should be
confirmed in the clinical setting in PDAC patients.
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